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Abstract 
One of the most common type of primary
brain tumors in adults is the glioblastoma mul-
tiforme  (GBM)  (World  Health  Organization
grade IV astrocytoma). It is the most common
malignant and aggressive form of glioma and it
is  among  the  most  lethal  ones.  Poly  (ADP-
ribose) polymerase 1 (PARP-1) gene, located to
1q42, plays an important role for the efficient
maintenance of genome integrity. PARP-1 pro-
tein is required for the apoptosis-inducing fac-
tor (AIF) translocation from the mitochondria
to  the  nucleus.  PARP-1 is  proteolytically
cleaved at the onset of apoptosis by caspase-3.
Microarray analysis of PARP-1gene expression
in  more  than  8000  samples  revealed  that
PARP-1 is  more  highly  expressed  in  several
types of cancer compared with the equivalent
normal tissues. Overall, the most differences
in PARP-1gene expression have been observed
in breast, ovarian, endometrial, lung, and skin
cancers,  and  non-Hodgkin’s  lymphoma.  We
evaluated the expression of PARP-1 protein in
normal  brain  tissues  and  primary  GBM  by
immunohistochemistry.  Positive  nuclear
PARP-1 staining was found in all samples with
GBM, but not in normal neurons from controls
(n=4) and GBM patients (n=27). No cytoplas-
mic staining was observed in any sample. In
conclusion, PARP-1 gene is expressed in GBM.
This finding may be envisioned as an attempt
to trigger apoptosis in this tumor, as well as in
many other malignancies. The presence of the
protein exclusively at the nucleus further sup-
port  the  function  played  by  this  gene  in
genome integrity maintenance and apoptosis.
Finally, PARP-1 staining may be used as GBM
cell marker.
Introduction
Glioblastoma  multiforme  (GBM),  or  World
Health Organization (WHO) grade IV astrocy-
toma,  is  the  most  common  type  of  primary
brain  tumor  in  adults.  In  addition,  it  is  the
most malignant and aggressive form of glioma
and among the most lethal ones because of its
highly  invasive  potential  and  least  effective
treatment  available  among  solid  tumors.1
Various genetic alterations lead to the develop-
ment  of  malignant  phenotype  expression  in
human  GBM.2,3 Heterogeneous  pathological
features  associated  with  complex  molecular
heterogeneity are the major problems for the
development of effective drug targets.4,5
GBMs can arise either de novo (primary) or
progress to GBM from low grade gliomas (sec-
ondary) with two distinct molecular pathways.3
Significant indicators of anaplasia in gliomas
include:  atypia  (coarse  nuclear  chromatin,
nuclear  pleomorphism,  multinucleation),
mitotic activity, cellularity, microvascular pro-
liferation,  and  necrosis.  Necrosis  with  the
microvascular or endothelial cell proliferations
is a histological hallmark of glioblastoma.3-5
Poly  (ADP-ribose)  polymerase  1  (PARP-1)
gene, located to 1q42, is 43 kb-long and divided
into  23  exons  (OMIM  173870).  Grube  and
Burkle6 suggested that a higher PARP-1 action
capacity may contribute to an efficient mainte-
nance of genome integrity. Yu et al.7 showed
that PARP-1 activation is required for translo-
cation of apoptosis-inducing factor (AIF) from
the mitochondria to the nucleus. PARP-1 pro-
tein is then proteolytically cleaved at the onset
of apoptosis by caspase-3;8 furthermore, PARP-
1 activity and poly (ADP-ribose) (PAR) poly-
mer, mediate PARP-1-induced cell death.8,9
Genetic and pharmacological studies found
that overexpression of PARP-1 is a key media-
tor of programmed-necrotic cell death in vivo.
In addition, PARP-1 appears to be also involved
in programmed cell death processes, such as
apoptosis  or  macroautophagocytotic  cell
death.10 Microarray  analysis  showed  that
PARP-1 mRNA expression in histologically nor-
mal tissues is low and uniform across a wide
variety  of  tissues.11 Furthermore,  microarray
analysis of PARP-1 gene expression in more
than  8000  samples  revealed  that  PARP-1 is
more  highly  expressed  in  several  types  of
tumors compared with the equivalent normal
tissue. Overall, the most striking differences in
PARP-1 gene expression have been observed in
breast, ovarian, endometrial, lung, skin can-
cers, and non-Hodgkin’s lymphoma.11
The present study was undertaken to evalu-
ate the expression of PARP-1 protein in normal
brain  tissues  and  primary  glioblastomas
(grade IV WHO) with  immunohistochemistry.
Materials and Methods 
Patient and control brain samples
The comparison has been made between: i)
4  normal  tissues  brain  removed  with  post
mortem autopsy  by  normal  donors  (2  males
and 2 females); ii) 27 non-tumor peripheral
tissues brain removed during surgical resec-
tion on patients with GBM and 27 tumor tis-
sues WHO grade IV GBM, specifically, by 14
male patients (58.3±10.0 years) and 13 female
patients (58.3±12.6 years) (Table 1).
Diagnoses of GBM were made on histologi-
cal  sections  stained  with  hematoxylin-eosin
and the sections were evaluated by at least two
operators. The protocol was approved by the
internal  Institutional  Review  Board  and  an
informed written consent was obtained from
each  patient  with  GBM  or,  if  deceased,  by
his/her relatives.
Immunohistochemical staining
Brain sections (4 μm thick) were obtained
from  all  normal  donors  and  GMB  patients.
Brain  sections  from  GBM  patients  included
both GBM and normal tissue (Table 1). All sec-
tions were formalin-fixed and paraffin-embed-
ded following standard methods.
PARP-(F-2), a mouse monoclonal antibody
raised against PARP-1 protein, was used for
immunohistochemistry  (Santa  Cruz
Biotechnology,  Inc.,  Heidelberg,  Germany)
PARP-1  (F-2):  sc-8007).  As  indicated  by  the
manufacturer  instructions,  this  antibody,  at
the dilution of 1:300, has been shown to reli-
ably  recognize  PARP-1  proteins  in  glioblas-
tomas and normal brain by immunohistochem-
istry. Slides were deparaffinized, rehydrated,
subjected to three 5-min cycles in a microwave
at 360 W in citrate buffer, preincubated in 3%
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H2O2 in citrate buffer, and thoroughly washed
in 50 mm Tris-Cl (pH 7.4), 150 mm NaCl Tris
buffered saline (TBS) containing 0.05% Tween
20  (washing  buffer).  Slides  were  then  pre-
incubated  with  3%  bovine  serum  albumin
(BSA) in TBS for 30 min, incubated with 1:300
dilution of anti-PARP-1 antibody in TBS con-
taining 1% BSA, thoroughly washed in wash-
ing buffer before detection with the LSAB 2 kit
(anti  mouse,  biotinylated  and  peroxidase-
labeled  streptavidin)  and  3,3-diaminobenzi-
dine-4HCl (DAB; Dako, Carpinteria, CA, USA)
from  Dako,  following  the  instructions  con-
tained in the kit. After detection, the sections
were counterstained with haematoxylin, dehy-
drated and mounted in xylen-based DPX moun-
tant (BDH, Pool, UK).12
Microscopic evaluation
Slides  were  observed  and  cells  visually
scored at 20X and 40X. To evaluate the percent-
age of positive tumor cells, microscopic fields
were chosen such that non-tumor cells were
also included. The fraction of PARP-1 positive
cells was evaluated independently in a blinded
fashion by two co-authors. No significant dif-
ference  was  observed  between  the  two
observers. 
Statistical analysis
Results are expressed as mean±SEM. Data
were analyzed by chi-square test and statistical
analysis was performed with Graph Pad Prism
5 software (Graph Pad Software, Inc. La Jolla,
CA,  USA).  The  statistical  significance  was
accepted for the p value lower than 0.05.
Results
Normal  tissues  (4  autopsies  and  27  non-
tumoral tissue of the same subjects with brain
GBM) did not show any nuclear or cytoplasmic
signal for the protein PARP-1 (Table 1, Figure
1A). The expression of PARP-1 was also evalu-
ated in 27 samples of GBM, PARP-1 positive
nuclear signal was present in all 27 samples
with  the  mean  of  nuclei  involved  of
87.03±5.04% (P<0.005). No cytoplasmic stain-
ing  was  observed  in  the  samples  (Table  1,
Figure  1B).  The  signal  was  present  on  the
nuclear membrane and nuclear chromatin.
Discussion 
This study showed that PARP-1 protein is
detectable in GBM cells, but is undetectable in
normal brain tissue. The protein seems to be
exclusively  localized  in  the  nucleus.  This
observation suggests that PARP-1 may play a
role in this tumor and that the presence of the
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Table 1. Expression PARP-1 protein in WHO glioblastoma multiforme grade IV astrocytoma. 
Sex Age (years) Brain localization Histological diagnosis Positive cell nuclei (%)
Case 1 Male 41 Right parietal lobe Glioblastoma IV WHO 95
Case 2 Male 61 Right temporal lobe Glioblastoma IV WHO 85
Case 3 Male 51 Left temporal lobe Glioblastoma IV WHO 90
Case 4 Male 67 Right temporal lobe Glioblastoma IV WHO 90
Case 5 Male 66 Right frontal lobe Glioblastoma IV WHO 80
Case 6 Male 68 Left parietal lobe Glioblastoma IV WHO 85
Case 7 Male 60 Left frontal lobe Glioblastoma IV WHO 90
Case 8 Male 68 Right frontal lobe Glioblastoma IV WHO 85
Case 9 Male 66 Right frontal lobe Glioblastoma IV WHO 90
Case 10 Male 53 Right parietal lobe Glioblastoma IV WHO 95
Case 11 Male 51 Left temporal lobe Glioblastoma IV WHO 80
Case 12 Male 60 Left frontal lobe Glioblastoma IV WHO 85
Case 13 Male 38 Left occipital lobe Glioblastoma IV WHO 85
Case 14 Male 66 Left occipital lobe Glioblastoma IV WHO 80
Case 15 Female 50 Left frontal lobe Glioblastoma IV WHO 95
Case 16 Female 69 Left frontal lobe Glioblastoma IV WHO 90
Case 17 Female 66 Left frontal lobe Glioblastoma IV WHO 85
Case 18 Female 43 Right temporal lobe Glioblastoma IV WHO 90
Case 19 Female 62 Right temporal lobe Glioblastoma IV WHO 80
Case 20 Female 60 Right frontal lobe Glioblastoma IV WHO 90
Case 21 Female 67 Left frontal lobe Glioblastoma IV WHO 95
Case 22 Female 28 Right temporal lobe Glioblastoma IV WHO 80
Case 23 Female 50 Brain ventricle Glioblastoma IV WHO 85
Case 24 Female 75 Right frontal lobe Glioblastoma IV WHO 90
Case 25 Female 62 Left frontal lobe Glioblastoma IV WHO 80
Case 26 Female 60 Left frontal lobe Glioblastoma IV WHO 90
Case 27 Female 66 Left frontal lobe Glioblastoma I VWHO 85
Autopsy 1 Male 66 Right frontal lobe Normal Not applicable
Autopsy 2 Male 54 Brain ventricle Normal Not applicable
Autopsy 3 Female 41 Right parietal lobe Normal Not applicable
Autopsy 4 Female 70 Right temporal lobe Normal Not applicable[European Journal of Histochemistry 2012; 56:e9] [page 47]
protein may be used as a cell marker. Indeed,
previous  studies13,14 found  the  expression  of
PARP-1 in brain whit GBM, in normal brain
and in nucleus and cytoplasm of human neu-
rons, also Wharton et al. 200015 have observed
expression of PARP-1 in multicellular tumour
spheroids,  derived  from  human  glioma  cell
lines. 
PARP-1 gene plays a significant role in cell
death both in cell necrosis and in apoptosis.
Massive  DNA  damage  that  typically  results
from necrotic stimuli elicits a major increase
of PARP-1 activity, which rapidly depletes the
intracellular concentration of nicotine adenine
dinucleotide (NAD+) and ATP. Increased con-
sumption of ATP, in the effort to re-synthesize
NAD+, leads to energy crisis culminating in cell
death.16 This may in part justify the presence
of  PARP-1  protein  in  GBMs  and  in  other
tumors,  such  as  ovarian,  endometrial,  lung,
breast, skin cancers, and non-Hodgkin’s lym-
phoma,11 as  well  as  in  a  patients  with
Parkinson disease and multiple head and neck
squamous cell in whom we recently reported
an increased PARP-1 mRNA expression.17
The understanding of the mechanism that
activates  the  expression  of  PARP-1 gene
requires significant further work to character-
ize its inter-domain interactions and its DNA-
dependence, both at a structural and a func-
tional  level.18 Nonetheless,  Eustermann  and
colleagues  provided  valuable  insights  into
recognition of chromosomal DNA single-strand
breaks, the crucial first step of the activation
process, by PARP-1 DNA binding domain.18 In
fact, PARP-1 is a highly abundant chromatin-
associated  enzyme  present  in  all  higher
eukaryotic cell nuclei, where it plays key roles
in  maintenance  of  genomic  integrity,  chro-
matin remodeling, and transcriptional control.
PARP-1 gene product binds to DNA single- and
double-strand  breaks  through  an  N-terminal
region containing two zinc fingers, F1 and F2.
The C-terminal catalytic domain of the PARP-1
protein is activated via an unknown mecha-
nism, causing formation and addition of the
poly (adenosine diphospho-ribose) complex to
acceptor proteins including PARP-1 itself.19
Several  reports  from  various  laboratories
indicate that inhibition or absence of PARP-1
provides  remarkable  protection  in  disease
models, such as septic shock, diabetes, stroke,
myocardial  infarction,  and  ischemia,  which
are  characterized  predominantly  by  pro-
grammed-necrotic  cell  death.20 In  addition,
PARP-1 activation has been causally connected
to photoreceptor cell death;21 this observation
has  more  recently  been  confirmed  by  other
authors,22 who showed a causal involvement of
PARP-1 in retinal degeneration, a neurodegen-
erative diseases affecting photoreceptors and
causing blindness in humans. Some authors,
besides, observed that poly(ADP-ribose) poly-
merase-1  inhibitor,  increases  the  antitumor
activity  against  intracranial  melanoma,
glioma,  lymphoma,  hematological  neo-
plasias;23-25 these  data  suggest  the  potential
role that could have PARP-1 inhibitors in the
therapy against glioblastoma.
Activation  of  PARP-1 in  response  to  DNA
damage is an important mechanism to keep
homeostasis  or  to  trigger  apoptosis.  The
expression and function of PARP-1 has been
studied in primary human lung cell cultures
from normal human bronchial epithelial cells
(NHBEC) and peripheral lung cells (PLC) from
lung cancer patients grown as explant cultures
over a period of 12 weeks. PARP-1 protein was
expressed in all the cell culture derived from
bronchial  epithelium  explants.26 Overall,
recent data on PARP-1agree on the meaning of
this gene expression in tumors. Accordingly,
the results of this study indicate that PARP-1
gene may play a role in GBMs.
In  conclusion,  PARP-1  protein  (with  this
antibody) is detectable in the nuclei of all GBM
cells, but is undetectable in normal cells. Given
the role of PARP-1 protein in cell death (both
necrosis  and  apoptosis)  and  in  DNA  repair
mechanisms, it may be hypothesized that the
presence of PARP-1 protein in the nucleus of
the GBM is an attempt to trigger apoptosis in
this type of tumor as well as in many other can-
cers.11,17 In the context of the tumor biology,
this may be envisioned as a defense mecha-
nism regardless of the outcome on the progno-
sis of patients with GBM. Finally, the evidence
that  PARP-1  positive  staining  is  exclusively
present within the nucleus adds further evi-
dence for the above-mentioned role played by
this protein.
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